SAN FRANCISCO — The biotechnology industry tends to be overshadowed by the razzle-dazzle of high-tech companies like Apple, Facebook and Google, particularly in the Bay Area.
Now, though, the biotech business is experiencing an almost unprecedented boom of its own. Money is flowing into the industry as never before. Stock prices are high, and drug approvals are up. And perhaps most important, some of the new drugs represent major advances against diseases like cancer, hepatitis C and cystic fibrosis.
Image: Michael Miller, Gilead’s director of clinical virology, in the company’s antiviral lab in Foster City, Calif. Money is flowing into the biotech industry as never before. Credit Peter DaSilva for The New York Times
